Dr. Olszanski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
333 Cottman Ave
Medical Staff Office
Philadelphia, PA 19111Phone+1 215-728-6900Fax+1 215-214-3229- Is this information wrong?
Education & Training
- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Clinical Pharmacology, 2002 - 2004
- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 1999 - 2002
- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 1996 - 1999
- Rutgers New Jersey Medical SchoolClass of 1996
- University of MontanaB.S, Pharmacy, 1985 - 1990
Certifications & Licensure
- NH State Medical License 2004 - Present
- PA State Medical License 2009 - 2024
- VT State Medical License 1998 - 2004
- American Board of Internal Medicine Medical Oncology
- American Board of Clinical PharmacologyClinical Pharmacology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Accelerating Anticancer Agent Development and Validation American Association for Cancer Research, 2006
- Methods in Clinical Cancer Research American Association for Cancer Research, 2003
- Join now to see all
Clinical Trials
- Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2007 Mar 01
- A Study of of MORAb-004 in Subjects With Solid Tumors Start of enrollment: 2009 Mar 01
- A Safety Study of Oral ZSTK474 in Patients With Cancer Start of enrollment: 2011 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.Dejan Juric, Minal Barve, Ulka Vaishampayan, Desamparados Roda, Aitana Calvo, Noelia Martinez Jañez, Jose Trigo, Alastair Greystoke, R Donald Harvey, Anthony J Olszans...> ;Cancer Medicine. 2024 Mar 1
- Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies.Diana Restifo, Joseph R McDermott, Dusica Cvetkovic, Troy Dos Santos, Charline Ogier, Aizhan Surumbayeva, Elizabeth A Handorf, Caleb Schimke, Charlie Ma, Kathy Q Cai, ...> ;Molecular Cancer Therapeutics. 2023 Oct 2
- 8 citationsPhase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.Drew W Rasco, Theresa Medina, Pippa Corrie, Anna C Pavlick, Mark R Middleton, Paul Lorigan, Chris Hebert, Ruth Plummer, James Larkin, Sanjiv S Agarwala, Adil I Daud, J...> ;Cancer Chemotherapy and Pharmacology. 2023 Jul 1
- Join now to see all
Journal Articles
- Phase I dose-escalation study of LCL161, an oral IAP inhibitor, in patients with advanced solid tumors.Infante JR, Dees EC, Olszanski AJ, JCO
- Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A Phase II trial.Slingluff CL, Petroni GR, Molhoek KR, Olszanski AJ, CCR
- Phase I study of axitinib combined with paclitaxel, docetaxel, or capecitabine in patients with advanced solid tumors.Martin LP, Kozloff MF, Herbst RS et al. and Olszanski AJ, British Journal of Cancer, 107; 1268-1276
- Join now to see all
Abstracts/Posters
- Dose-escalation Phase 1 study of cabazitaxel (Cbz) + gemcitabine (Gem) in patients (pts) with metastatic or unresectable advanced solid malignancy.Rixe O, Puzanov I., LoRusso P, et al and Olszanski AJ, ESMO (2012) Abstract 497P
- Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: Phase II trial with correlative studies.Slingluff CL, et al and Olszanski AJ, ASCO (2012) Abstract 8530
- Phase 1 and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.Faivre S, Olszanski AJ, ASCO (2012) Abstract 2554
- Join now to see all
Press Mentions
- Could a Blood Test Effectively Screen for Cancers?September 20th, 2022
- New Cell Therapy Outperforms Immunotherapy in MelanomaSeptember 11th, 2022
- More False Than True PositivesSeptember 11th, 2022
- Join now to see all
Grant Support
- Cancer Genome Institute Clinical Research Pilot GrantFox Chase Cancer Center2013–Present
Committees
- Chair, Pharmacy & Therapeutics Committee, FCCC 2012 - Present
- Senior Medical Advisor, FCCC Cancer Genome Institute 2012 - Present
- Chair, FCCC Genomic Advisory Board 2012 - Present
- Member, Data Safety Monitoring Board, FCCC 2012 - Present
- Member, NCCN Investigator Steering Committee 2012 - Present
- Chair, American Board of Clinical Pharmacology, Credentials Committee 2011 - Present
- Member, National Comprehensive Cancer Network, Melanoma Panel 2010 - Present
- Member, Research Reivew Committee, FCCC 2009 - Present
Professional Memberships
- Member
- Member
Hospital Affiliations
- Temple University HospitalPhiladelphia, Pennsylvania
- Fox Chase Cancer CenterPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: